To view this page ensure that Adobe Flash Player version 11.1.0 or greater is installed.

Editorial Paediatric Oncology Is Knowledge Better than Ignorance in Paediatric Oncogenetics? Identifying Biological Causes and Searching for Meaning Franck Bourdeaut 1–3 1. Paris Sciences-Lettres Research University, Institut Curie, Departement d’Oncologie Pediatrique-Adolescents et Jeunes adultes; 2. SiRIC Institut Curie, Laboratoire de Recherche Translationnelle en Oncologie Pediatrique, Institut Curie; 3. INSERM U830, Genetique et Biologie des Cancers, Institut Curie, Paris, France Abstract The identification of predisposing germline mutations is an expanding field in paediatric oncology. Next generation sequencing performed on tumours actually expand the indications of genetic counselling, potentially to almost all children affected by cancer. However, little is known about the actual medical benefit of this knowledge. Parents and caregivers need to define, altogether, when and how knowledge is better than ignorance, before entering such a procedure. Keywords Oncogenetics, pediatrics, knowledge, ignorance, ethics Disclosure: Franck Bourdeaut has nothing to disclose in relation to this article. This article is a short opinion piece and has not been submitted to external peer reviewers. No funding was received in the publication of this article. Acknowledgements: Franck Bourdeaut acknowledges Dominique Davous, Anne Auvrignon, Brice Fresneaux, Etienne Seigneur, Paul-Loup Weil-Dubuc and all the “Ethic Group of Parents and Care-givers in Pediatric Oncology”, Espace Ethique Ile de France, Paris. Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation and reproduction provided the original author(s) and source are given appropriate credit. Received: 28 April 2016 Published Online: 24 May 2016 Citation: European Oncology & Haematology, 2016;12(1):21–2 Correspondence: Franck Bourdeaut, Departement d’Oncologie Pediatrique-Adolescents et Jeunes adultes, 26 rue d’Ulm, 75005 Paris, France. E: franck.bourdeaut@curie.fr The rate of childhood cancer caused by a genetic predisposition is now estimated around 8.5%. 1 While proposing a genetic counselling has been classically considered as part of good clinical practice for few malignancies (retinoblastoma, adrenocortical tumours, choroid plexus carcinoma), its actual requirement and relevance was for long deemed questionable for most paediatric cancers. However, next generation sequencing (NGS) has opened new areas for the practice of genetic testing in paediatric oncology. It has first permitted the discovery of new predisposition syndromes in patients for whom no genetic counselling would have been proposed a few years ago. 1–4 It has also systematised the requirement of constitutional DNA for the analysis of tumour genetics – and thereby, considerably enlarged the need for consents concerning genetic testing in the germline. 5 Some works would suggest that genetic counselling should now be systematically offered to all families of children with cancer, regardless of the histology or familial and personal medical history 6 - and potentially, regardless of the actual proof of any medical benefit of genetic testing for the patients and their family. The principle supporting such a way of doing would rely on the assumption that knowing is better than ignoring – and, consequently, increasing the knowledge either for oneself as a patient, or for the scientific and medical community, is ipso facto bearing some improvement, at any level. However, in the case of paediatric oncogenetics, the collusion between biological research, clinical research and daily clinical practice exquisitely raises ethical issues, renewed by the development of NGS. The core issue may be summarised by this fundamental question: is knowledge unquestionably better than ignorance? In other words, what are the positive and negative moral impacts of knowing and ignoring TOU CH MED ICA L MEDIA that one carries a deleterious mutation, which exposes to a variably estimated over-risk of cancer? Of course, when the medical benefit of knowing is obvious, leading to well-established and consensual follow- up procedures (early diagnosis of RB1 mutation, for example), ethical issues may be easily solved – but such situations currently represent a minority in paediatric oncogenetics. Then, the balance of right to know versus to ignore, and duty to know versus to ignore 7 may help unravelling potential benefits and side effects of each posture. Defenders of the right to know argue that knowledge increases autonomy – which implies that critical decisions on important aspects of life may be positively changed by knowing what one’s genes are. While this may apply for adults, to what extent is that true for children, whose autonomy is related to their age? Knowing about one’s gene is definitive – no way to withdraw one’s consent once the information is given. Therefore, applying the principle of maximal autonomy implies that deciding for a child to know whether he is actually bearing a predisposition relies on the certitude that it will positively change his life while he is a child – and that waiting for his adulthood is not an option. This can be true when age at tumour occurrence is young, and when some medical action can be taken to prevent the cancer development. This implies that the benefit of early diagnosis and the precise follow-up procedures are established, which, again, is rather rare in paediatric oncology. Another presumably positive effect of knowing consists in protecting other family members from cancer or from the “bad surprise” to discover, too late, that one is prone to developing cancer. In paediatrics, 21